NCT07774533RecruitingEarly phase 1
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
Clinical Evaluation of a 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Patients With Osteosarcoma
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET/CT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 11 Aug 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 5 Aug 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT07774533
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 16
- From 1 Apr 2026 to the primary completion date, 5 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe uncontrolled systemic disease or medical condition that, in the investigator's judgment, may interfere with study participation or image interpretation.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.
Other
- Pregnant or breastfeeding.
- Unable to undergo PET/CT examination.
Who the study is looking for
- Age ≥10 years.
- Histologically confirmed osteosarcoma.
- Relapsed or refractory disease following failure of first- or second-line systemic therapy.
- Ability to understand the study procedures and provide written informed consent (or assent with parental/legal guardian consent, where applicable).
Age in the registry: 10 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.